Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

(2013) M. Helen Huls et al.   Jove-Journal of Visualized Experiments

Good T cells for bad B cells

(2012) L. J. N. Cooper et al.   BLOOD

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR

(2012) H. Torikai et al.   BLOOD

Adoptive T-cell therapy improves treatment of canine non–Hodgkin lymphoma post chemotherapy

(2012) Colleen M. O'Connor et al.   Scientific Reports

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies

(2011) H. Singh et al.   CANCER RESEARCH

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells

(2010) C. H. J. Lamers et al.   BLOOD

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

(2010) B. Jena et al.   BLOOD

Adoptive Cell Therapy

(2010) Richard A. Morgan et al.   CANCER JOURNAL

Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response

(2010) A Hombach et al.   GENE THERAPY

A Transposon and Transposase System for Human Application

(2010) Perry B Hackett et al.   MOLECULAR THERAPY

piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage Malignancies

(2009) Pallavi V. Raja Manuri et al.   HUMAN GENE THERAPY

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

(2008) B. G. Till et al.   BLOOD

Redirecting Specificity of T-Cell Populations For CD19 Using the Sleeping Beauty System

(2008) H. Singh et al.   CANCER RESEARCH

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE